| First Author | Kipari T | Year | 2013 |
| Journal | FASEB J | Volume | 27 |
| Issue | 4 | Pages | 1519-31 |
| PubMed ID | 23303209 | Mgi Jnum | J:197640 |
| Mgi Id | MGI:5494211 | Doi | 10.1096/fj.12-219105 |
| Citation | Kipari T, et al. (2013) 11beta-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis. FASEB J 27(4):1519-31 |
| abstractText | 11beta-Hydroxysteroid dehydrogenase type-1 (11beta-HSD1) converts inert cortisone into active cortisol, amplifying intracellular glucocorticoid action. 11beta-HSD1 deficiency improves cardiovascular risk factors in obesity but exacerbates acute inflammation. To determine the effects of 11beta-HSD1 deficiency on atherosclerosis and its inflammation, atherosclerosis-prone apolipoprotein E-knockout (ApoE-KO) mice were treated with a selective 11beta-HSD1 inhibitor or crossed with 11beta-HSD1-KO mice to generate double knockouts (DKOs) and challenged with an atherogenic Western diet. 11beta-HSD1 inhibition or deficiency attenuated atherosclerosis (74-76%) without deleterious effects on plaque structure. This occurred without affecting plasma lipids or glucose, suggesting independence from classical metabolic risk factors. KO plaques were not more inflamed and indeed had 36% less T-cell infiltration, associated with 38% reduced circulating monocyte chemoattractant protein-1 (MCP-1) and 36% lower lesional vascular cell adhesion molecule-1 (VCAM-1). Bone marrow (BM) cells are key to the atheroprotection, since transplantation of DKO BM to irradiated ApoE-KO mice reduced atherosclerosis by 51%. 11beta-HSD1-null macrophages show 76% enhanced cholesterol ester export. Thus, 11beta-HSD1 deficiency reduces atherosclerosis without exaggerated lesional inflammation independent of metabolic risk factors. Selective 11beta-HSD1 inhibitors promise novel antiatherosclerosis effects over and above their benefits for metabolic risk factors via effects on BM cells, plausibly macrophages. |
